Modulation of Lnc05 expression
Provided herein are methods, compounds, and compositions for reducing expression of Inc05 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cancer in an individual.
1. A method of treating cancer in an individual having cancer comprising administering a compound comprising a modified oligonucleotide having a nucleobase sequence complementary to a Inc05 nucleic acid to the individual, thereby treating the cancer in the individual.
2. The method of claim 1 , wherein the compound is single-stranded.
3. The method of claim 1 , wherein the compound is double-stranded.
4. The method of claim 1 , wherein the modified oligonucleotide is 12 to 30 linked nucleosides in length.
5. The method of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar moiety, or at least one modified nucleobase.
6. The method of claim 5 , wherein the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage, the at least one modified sugar is a bicyclic sugar or 2′-O-methyoxyethyl, and the at least one modified nucleobase is a 5-methylcytosine.
7. The method of claim 5 , wherein at least one modified sugar comprises a 4′-CH(CH3)-O-2′ bridge or a 4′-(CH2)n-O-2′ bridge, wherein n is 1 or 2.
8. The method of claim 1 , wherein the modified oligonucleotide comprises:
a gap segment consisting of linked deoxynucleosides;
a 5′ wing segment consisting of linked nucleosides;
a 3′ wing segment consisting of linked nucleosides;
wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
9. The method of claim 8 , wherein the modified oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence consisting of the nucleobase sequence of SEQ ID NO: 8, wherein the modified oligonucleotide comprises:
a gap segment consisting of 10 linked deoxynucleosides;
a 5′ wing segment consisting of 5 linked nucleosides;
a 3′ wing segment consisting of 5 linked nucleosides;
wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment, each nucleoside of each wing segment comprises a 2′-O-methoxyethyl nucleoside, each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage, and each cytosine of the modified oligonucleotide is a 5-methylcytosine.
10. The method of claim 1 , wherein the Inc05 nucleic acid has the sequence of any of SEQ ID NOs: 1-5.
11. The method of claim 10 , wherein the modified oligonucleotide is at least 90% complementary to the Inc05 nucleic acid.
12. The method of claim 10 , wherein the modified oligonucleotide is at least 95% complementary to the Inc05 nucleic acid.
13. The method of claim 10 , wherein the modified oligonucleotide is 100% complementary to the Inc05 nucleic acid.